ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   


By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Daiichi Sankyo, Inc. 

U.S. Corporate Headquarters
Two Hilton Court
Parsippany  New Jersey  07054  U.S.A.
Phone: 973-944-2600 Fax: 973-359-2645


SEARCH JOBS

About Daiichi Sankyo, Inc.

Daiichi Sankyo Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Tokyo-based Daiichi Sankyo Co., Ltd., which is a global pharmaceutical innovator.

The headquarters company was established in 2005 from the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world.

A central focus of Daiichi Sankyo's research and development is cardiovascular disease, including therapies for dyslipidemia, hypertension, diabetes and acute coronary syndrome. Also important to the company is the discovery of new medicines in the areas of infectious diseases, cancer, bone and joint diseases, and immune disorders.


This div will be replaced



 Key Statistics


Email:
Ownership: Public

Web Site: Daiichi Sankyo, Inc.
Employees: 3,000 in the U.S.
Symbol: 4568.t
 



Industry
Pharmaceutical






 Company News
Agendia BV Announces New Agreement With Daiichi Sankyo, Inc. (4568.t) To Support Oncology Drug Development 4/24/2014 7:58:18 AM    More...
Ken Keller Named President, U.S. Commercial, Daiichi Sankyo, Inc. (4568.t) 4/18/2014 8:55:42 AM    More...
Astellas Pharma Inc. (ALPMY) And Daiichi Sankyo, Inc. (4568.t) Form Compound Library Sharing Partnership 3/20/2014 10:13:49 AM    More...
Provepharm Announces That Its Partner In Japan, Daiichi Sankyo, Inc. (4568.t) Has Filed An NDA For The Marketing Of The Methylene Blue Injection Medicinal Product In Japan, Made Out Of Proveblue® Methylene Blue Active Substance 3/19/2014 10:27:45 AM    More...
Daiichi Sankyo, Inc. (4568.t) Pledges Bold Action On Ranbaxy Laboratories (RANBAXY.BO) Production Problems 1/31/2014 7:14:40 AM    More...
Pieris Achieves Fourth Milestone Payment In Daiichi Sankyo, Inc. (4568.t) Collaboration To Develop Anticalin® Therapeutics 1/13/2014 7:53:14 AM    More...
Daiichi Sankyo, Inc. (4568.t) Submits SAVAYSA™ (Edoxaban) Tablets New Drug Application To The FDA For Once-Daily Use For Stroke Risk Reduction In Atrial Fibrillation And For The Treatment And Prevention Of Recurrence Of Venous Thromboembolism 1/10/2014 10:21:12 AM    More...
Daiichi Sankyo, Inc. (4568.t), Virtici And Celdara Medical Announce Collaboration To Identify And Progress High Potential Therapeutics 1/8/2014 9:59:42 AM    More...
Daiichi Sankyo, Inc. (4568.t) Submits Edoxaban Marketing Authorization Application To The EMA For Once-Daily Use For Stroke Prevention In Atrial Fibrillation And For The Treatment And Prevention Of Recurrence Of Venous Thromboembolism 1/7/2014 11:04:25 AM    More...
Daiichi Sankyo, Inc. (4568.t) To Help Ranbaxy Laboratories (RANBAXY.BO) Meet FDA Norms 12/19/2013 7:07:51 AM    More...
12345678910...